ArticleFrontiers in pediatrics2025
Novel serum biomarker for powerfully predicting pediatric simple febrile seizures.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Current model or biomarkers are far from satisfactory to predict pediatric simple febrile seizures (SFS). This study aimed to explore novel serum biomarkers in children with SFS and analyze their clinical significance. Methods: A total of 57 SFS children admitted to the pediatric ward of Jinhua Maternal and Child Health Hospital from June 2022 to October 2024 were enrolled as the observation group, 61 sepsis patients and 45 healthy children from the pediatric health clinic during the same period were included as the control groups. Serum levels of 25-hydroxyvitamin D and diverse cytokines were measured using enzyme-linked immunosorbent assay (ELISA). Univariate logistic regression was used to identify the predictive ability of risk factors for SFS. Results: The SFS group exhibited significantly lower levels of IL-17 (SFS: 5 vs. Health: 12 and Sepsis: 16) compared to the control groups. Conversely, the SFS group showed significantly higher levels of pro-inflammatory cytokines (IFN-α: 22 vs. 4 and 5; and IL-10: 12 vs. 10 and 9) than the control groups. ROC curve revealed that during SFS episodes, IFN-α can powerfully in discriminating SFS and health cohorts. Conclusion: Serum level of IFN-α hold significant predictive value for SFS occurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.